ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • February 1, 2018 - January 31, 2020
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Whelan M.D., Kimberly   Investigator